HUTCHMED (NASDAQ:HCM) Rating Lowered to Neutral at The Goldman Sachs Group

The Goldman Sachs Group downgraded shares of HUTCHMED (NASDAQ:HCM) from a buy rating to a neutral rating in a research report released on Wednesday, Analyst Price Targets reports. The Goldman Sachs Group currently has $46.00 price target on the stock.

Several other analysts have also recently weighed in on HCM. Cantor Fitzgerald raised their price target on HUTCHMED from $40.00 to $45.00 and gave the company an overweight rating in a report on Tuesday, July 13th. Zacks Investment Research raised HUTCHMED from a sell rating to a hold rating in a report on Tuesday, September 14th. Finally, Jefferies Financial Group started coverage on HUTCHMED in a research note on Tuesday, August 3rd. They issued a buy rating and a $52.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, HUTCHMED has an average rating of Buy and a consensus price target of $44.60.

NASDAQ HCM opened at $36.56 on Wednesday. HUTCHMED has a 12-month low of $23.67 and a 12-month high of $43.94. The firm’s 50 day moving average is $39.91 and its 200-day moving average is $33.44. The company has a quick ratio of 4.30, a current ratio of 4.41 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $6.32 billion, a PE ratio of -40.62 and a beta of 1.08.

A number of large investors have recently made changes to their positions in the business. Ensign Peak Advisors Inc raised its stake in HUTCHMED by 5.8% during the second quarter. Ensign Peak Advisors Inc now owns 5,500 shares of the company’s stock valued at $216,000 after buying an additional 300 shares during the last quarter. Quadrant Capital Group LLC raised its stake in shares of HUTCHMED by 227.3% in the second quarter. Quadrant Capital Group LLC now owns 635 shares of the company’s stock worth $25,000 after purchasing an additional 441 shares during the last quarter. Caisse DE Depot ET Placement DU Quebec raised its stake in shares of HUTCHMED by 4.4% in the first quarter. Caisse DE Depot ET Placement DU Quebec now owns 12,088 shares of the company’s stock worth $341,000 after purchasing an additional 514 shares during the last quarter. Stifel Financial Corp raised its stake in shares of HUTCHMED by 1.5% in the first quarter. Stifel Financial Corp now owns 37,200 shares of the company’s stock worth $1,051,000 after purchasing an additional 555 shares during the last quarter. Finally, United Capital Financial Advisers LLC raised its stake in shares of HUTCHMED by 4.8% in the second quarter. United Capital Financial Advisers LLC now owns 12,613 shares of the company’s stock worth $495,000 after purchasing an additional 581 shares during the last quarter. Institutional investors and hedge funds own 26.60% of the company’s stock.

HUTCHMED Company Profile

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. It operates in two segments, Oncology/Immunology and Other Ventures. It manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical, and consumer health products.

Featured Story: Trading Options- What is a Strangle?

Analyst Recommendations for HUTCHMED (NASDAQ:HCM)

Receive News & Ratings for HUTCHMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHMED and related companies with MarketBeat.com's FREE daily email newsletter.